Skip to main content
Figure 2 | BMC Psychiatry

Figure 2

From: Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder

Figure 2

Specificity and sensitivity for predicting significant weight gain of ≥ 10 kg at 30-week endpoint. Specificity and sensitivity (%) for predicting significant weight gain of ≥ 10 kg at 30-week endpoint were estimated via leave-one-out cross validation using data from Study 1 and different sets of predictors. The black symbols indicate prediction rules obtained using single cut-offs for early weight change at Weeks 1, 2, 3, and 4 (on horizontal axes). The white symbols indicate prediction rules incorporating baseline characteristics only (shown for Week = 0), and a combination of baseline characteristics and early weight change at Weeks 1, 2, 3, and 4.

Back to article page